Mobile

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Efficacy and Safety of MK-0952 in Patients With Alzheimer’s Disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-003924-13

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of MK-0952 37.5 mg daily over a 4-week treatment period in improving cognitive function in patients with mild-to-moderate AD as assessed by the 0-hour to 24-hour difference in Word List Learning-Selective Reminding (WLL-SR) Summary Score and the 2-hour to 24-hour correct response percentage difference in the Word List Learning-Delayed Recognition (WLL-DR) test of the Computerized Neuropsychological Test Battery (CNTB); 2) To evaluate the safety and tolerability of MK-0952 37.5 mg daily in patients with mild-to-moderate AD.

Critère d'inclusion

  • Alzheimer's disease

Liens